GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $1.95 $2.64 Friday, 19th Apr 2024 CHRS stock ended at $2.07. This is 3.50% more than the trading day before Thursday, 18th Apr 2024. During the day the stock fluctuated 7.18% from a day low at $1.95 to a day high of $2.09.
90 days $1.93 $2.97
52 weeks $1.44 $8.33

Historical Coherus BioSciences prices

Date Open High Low Close Volume
2023-10-19 $3.65 $3.65 $3.47 $3.55 1 627 088
2023-10-18 $3.70 $3.72 $3.51 $3.60 1 547 166
2023-10-17 $3.82 $3.98 $3.73 $3.73 1 046 562
2023-10-16 $3.80 $3.94 $3.69 $3.85 1 436 838
2023-10-13 $3.69 $3.81 $3.60 $3.81 2 078 479
2023-10-12 $3.86 $3.88 $3.66 $3.69 2 290 474
2023-10-11 $3.81 $3.97 $3.78 $3.82 1 635 450
2023-10-10 $3.65 $3.91 $3.62 $3.81 1 715 019
2023-10-09 $3.67 $3.73 $3.54 $3.63 1 989 871
2023-10-06 $3.41 $3.80 $3.37 $3.75 3 034 666
2023-10-05 $3.25 $3.48 $3.14 $3.47 3 354 309
2023-10-04 $3.39 $3.40 $3.15 $3.17 2 627 503
2023-10-03 $3.60 $3.60 $3.33 $3.35 2 323 405
2023-10-02 $3.80 $3.73 $3.59 $3.60 3 272 926
2023-09-29 $3.89 $3.93 $3.72 $3.74 2 348 529
2023-09-28 $4.00 $4.02 $3.83 $3.87 1 858 386
2023-09-27 $4.01 $4.09 $3.88 $3.97 1 884 696
2023-09-26 $4.00 $4.14 $3.93 $3.98 2 376 538
2023-09-25 $4.36 $4.36 $4.04 $4.05 2 788 886
2023-09-22 $4.15 $4.48 $4.14 $4.46 2 705 935
2023-09-21 $4.45 $4.47 $4.12 $4.14 3 719 851
2023-09-20 $4.56 $4.73 $4.51 $4.51 1 720 898
2023-09-19 $4.53 $4.62 $4.38 $4.61 2 353 285
2023-09-18 $4.86 $4.87 $4.37 $4.53 4 026 677
2023-09-15 $4.79 $4.97 $4.71 $4.92 16 669 156
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT